“Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%)” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s421. doi:10.25251/skin.8.supp.421.